EU Good Pharmacovigilance Practices (GVP)
The EU good pharmacovigilance practices — a modular set of guidelines (Modules I-XVI plus product/population-specific considerations) governing the safety surveillance of medicines across their lifecycle: the pharmacovigilance system and its master file, risk management plans, ICSR management, signal management, and post-authorisation safety studies.
What this does not cover
stated in the document's own scope- Covers post-authorisation safety monitoring of medicines; safety reporting during clinical trials is governed by the Clinical Trials Regulation.
- Provides pharmacovigilance guidance, not the manufacturing GMP that applies to making the product, which sits in the EU GMP Guide.
- Addresses human medicines; veterinary pharmacovigilance is governed under Regulation (EU) 2019/6.
- Sets the operational standard, with the binding duties residing in the EU pharmacovigilance legislation rather than in GVP itself.
Always verify against the current published text before relying on it for a submission or inspection.
Overview
The EU Good Pharmacovigilance Practices (GVP) are a modular set of guidelines describing how the safety of medicines authorised in the EU is monitored across their lifecycle. They span the pharmacovigilance system and its master file, quality systems and inspections, risk management planning, the management and reporting of individual case safety reports, signal management, periodic safety update reports, post-authorisation safety studies, safety communication and the handling of safety signals. Structured as numbered modules plus product- and population-specific considerations, GVP gives marketing-authorisation holders and authorities a common operating standard for pharmacovigilance activities and their documentation.
Scope & applicability
Marketing authorisation holders and competent authorities operating pharmacovigilance systems for EU-authorised medicines. Operated through EudraVigilance and the QPPV role.
Legal basis & how it acquires force
GVP gives operational detail to the EU pharmacovigilance legal framework — Regulation (EC) No 726/2004 and Directive 2001/83/EC as amended by the 2010 pharmacovigilance legislation, together with Commission Implementing Regulation (EU) 520/2012. The legal obligations sit in that legislation; GVP is the guidance published by EMA (in coordination with national competent authorities) on how to meet them. Following GVP is expected of marketing-authorisation holders because the underlying statutory duties, such as operating a pharmacovigilance system and reporting adverse reactions, are binding.
Document structure
| Part | Covers |
|---|---|
| Modules I–II | Pharmacovigilance systems and their quality systems, and the Pharmacovigilance System Master File |
| Modules III–IV | Pharmacovigilance inspections and audits |
| Module V | Risk management systems and risk management plans |
| Modules VI–VII | Management and reporting of adverse reactions and periodic safety update reports |
| Modules VIII–IX | Post-authorisation safety studies and signal management |
| Modules X–XVI plus specific considerations | Additional monitoring, safety communication, and product-/population-specific guidance |
Key requirements
- A defined pharmacovigilance system with a QPPV and a maintained PSMF
- Risk management plans proportionate to the product safety profile
- ICSR collection and expedited/periodic submission via EudraVigilance
- A documented signal-management process with defined timelines
Implementation tips
- Keep the PSMF continuously current — it is the first document requested at a PV inspection
- Align signal-management cadence and documentation with Module IX to withstand scrutiny
Revision notes
Modules have been revised individually since first publication in 2012; several (e.g. Module VI) were updated to reflect ISO/ICH E2B(R3) ICSR standards.
Where this control fails
live FDA enforcementLive FDA recalls SPEQ maps to this standard’s topics — a SPEQ interpretation, not an FDA classification.
International alignment
GVP incorporates the ICH pharmacovigilance standards — E2A definitions of serious and unexpected reactions, E2B for electronic case transmission, E2C for periodic benefit-risk reporting, and E2E for pharmacovigilance planning — and case reports flow through EudraVigilance in the E2B format. It is the EU counterpart to the US post-marketing safety-reporting framework under 21 CFR 314.80, and it operates alongside the Clinical Trials Regulation for safety reporting during trials.
EU GVP Modules: frequently asked questions
Quick answers to common questions about EU GVP Modules.
What are the EU GVP modules?
They are a modular set of Good Pharmacovigilance Practices guidelines published by EMA covering pharmacovigilance systems, the system master file, risk management, adverse-reaction reporting, periodic safety update reports, signal management, post-authorisation safety studies and safety communication, plus product- and population-specific considerations.
Are the GVP modules legally binding?
The modules are guidance. The binding obligations sit in the EU pharmacovigilance legislation — Regulation (EC) No 726/2004, Directive 2001/83/EC as amended, and Implementing Regulation (EU) 520/2012 — and GVP describes how marketing-authorisation holders and authorities meet those obligations.
How does GVP relate to ICH pharmacovigilance guidelines?
GVP incorporates the ICH E2 series — E2A definitions, E2B electronic transmission, E2C periodic reporting and E2E pharmacovigilance planning — and adverse-reaction cases are submitted through EudraVigilance in the ICH E2B format.
This standard in practice
Recall domain is a SPEQ mapping of this standard’s topics, not an FDA classification.